Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-7), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro and a Pro-Gly-Pro C-terminal extension designed to improve metabolic stability. CAS 80714-61-0, molecular formula C₃₇H₅₁N₉O₁₀S, molecular weight 813.95 g/mol.
Originally developed at the Institute of Molecular Genetics in Moscow, Semax has been studied in the context of central nervous system research, including investigations into BDNF and NGF expression regulation, neuroprotection models, and dopaminergic system modulation. Research has examined its pharmacological interactions with ACTH receptors and its effects in ischemia and oxidative stress cell culture models. It represents a well-characterized tool compound for studying ACTH-derived peptide pharmacology and neurotrophin regulation in vitro.
Supplied as a lyophilized powder. Each lot is independently tested by HPLC-UV at 218nm with a minimum purity threshold of ≥99.0%. Molecular identity confirmed by LC-MS prior to release. Certificate of Analysis available for every lot number.
For laboratory and in-vitro research use only. Not for human or veterinary use. Not FDA approved.